Nanotechnology offers many possibilities to improve
drug treatments, including with regard to
drug pharmacology. The current study reports a simple approach to improve
cisplatin efficacy in the treatment of
colon cancer through the creation of orally administered squalenoylated nanoparticles loaded with
cisplatin (SQ-CDDP NP). Cytotoxic effects of SQ-CDDP NP were assessed in human colonic cells and in mouse models of
intestinal cancer. In cell culture, SQ-CDDP NP exhibited at least 10-fold greater cytotoxic potency compared with uncomplexed
cisplatin, reflecting an enhancement in intracellular accumulation and
DNA platination. Mechanistic investigations showed that SQ-CDDP NP stimulated ROS production, expression of
heavy metal-inducible and stress-inducible genes, stress
kinase cascades, and apoptosis. In ApcMin/+ mice, a model of intestinal
tumorigenesis,
oral administration of SQ-CDDP NP curtailed spontaneous
tumor formation and
azoxymethane-induced colon
carcinogenesis with no apparent evidence of tissue toxicity. Our results offer preclinical validation of a nanocarrier formulation that can safely improve chemotherapeutic efficacy, address risks of drug resistance, and improve patient compliance by enabling
oral administration.
Cancer Res; 77(11); 2964-75. ©2017 AACR.